TY - JOUR T1 - mMRI at 3.0 T as an Evaluation Tool of Therapeutic Response to Neoadjuvant CRT in Patients with Advanced-stage Rectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 215 LP - 222 VL - 37 IS - 1 AU - ULRIKE I. ATTENBERGER AU - MELISSA M. ONG AU - NILS RATHMANN AU - FABIAN DOYON AU - PETER KIENLE AU - RALF-DIETER HOFHEINZ AU - LOTHAR R. PILZ AU - DIETMAR J. DINTER AU - STEFAN O. SCHOENBERG AU - DANIEL HAUSMANN Y1 - 2017/01/01 UR - http://ar.iiarjournals.org/content/37/1/215.abstract N2 - Aim: To assess whether multiparametric MRI (mMRI) can serve as a tool for evaluating response to chemoradiation therapy (CRT) in advanced-stage rectal cancer. Patients and Methods: Twenty-one patients underwent a mMRI protocol at 3T before and after CRT. Two experienced radiologists evaluated the MRI measurements and inter-reader correlation was assessed. Changes in functional parameters in relation to regression, as well as pT stage were analyzed. The perfusion parameters plasma flow (PF) and mean transit time (MTT) were calculated offline using the established UMM Perfusion tool. Results: Apparent diffusion coefficient values were significantly different among the different tumor RGs before CRT (p=0.041). Changes of dynamic contrast enhanced (DCE) MRI values did not reflect treatment response (PF: p=0.5; MTT: p=0.74). Conclusion: The results of our study population indicate that a high initial apparent diffusion coefficient value may be predictive of response to therapy following CRT. ER -